# A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

> **NCT06868212** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 400 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria (CSU)

## Interventions

- **DRUG:** Remibrutinib
- **DRUG:** Remibrutinib matching placebo
- **DRUG:** Dupilumab
- **DRUG:** Placebo solution for injection

## Key facts

- **NCT ID:** NCT06868212
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-11
- **Primary completion:** 2027-02-22
- **Final completion:** 2027-05-17
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06868212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06868212, "A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06868212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*